EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

A Randomized Trial on the Combined Effect of Ponesimod and Propranolol on Heart Rate, Cardiac Safety, and Pharmacokinetics in Healthy Adults

Sivi Ouwerkerk-Mahadevan iD, Tessa Hosman, Italo Poggesi iD, Eva Vets, Freya Rasschaert iD, Jay Ariyawansa, Jaya Natarajan, Maroesja van Nimwegen-Velthuis iD, Andrea Vaclavkova, Juan Jose Perez-Ruixo iD, Tatiana Sidorenko iD

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70341 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Sivi Ouwerkerk-Mahadevan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Johnson & Johnson, Beerse, Belgium. Hauptthemen laut MEDLINE: Heart Rate, Propranolol, Thiazoles, Sphingosine 1 Phosphate Receptor Modulators. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The objective of this phase 1 study was to evaluate the pharmacokinetics (PK), pharmacodynamics, and cardiac effect following administration of ponesimod (a selective sphingosine‐1‐phosphate receptor modulator) and propranolol in healthy adults. In treatment period (TP) 1, participants received ponesimod (2 mg). In TP2, if resting heart rate (HR) was ≥ 55 bpm, the ponesimod up‐titration regimen was initiated. Participants were randomized to TP2A (placebo plus ponesimod up‐titration) or TP2B (80 mg propranolol plus ponesimod up‐titration). Concomitant administration resulted in an increased bradyarrhythmic effect on HR versus ponesimod alone. The mean maximum difference in mean hourly HR from time‐matched baseline for TP2B compared with TP2A during the first 12 h post‐dose was −12.4 bpm. This was observed after the first dose of ponesimod, persisted for the first 4 doses, then decreased to −7.4 bpm post‐up‐titration. The lowest mean of the HR nadir in TP2B was 48.9 bpm (95% CI: 46.4–51.3). There was no significant difference in the occurrence of 1st degree AV block between groups and no occurrences of 2nd or higher degree AV block. No clinically relevant changes were observed in the PK of ponesimod or propranolol. Overall, 88.5% of participants experienced ≥ 1 AE during the study. In TP2, the most reported TEAEs (≥ 5%) considered related to ponesimod were fatigue (12 [25.5%]) and dizziness (10 [21.3%]). No deaths were reported. Co‐administration of ponesimod with propranolol resulted in a greater HR‐lowering effect compared to ponesimod alone, without significant changes in PK parameters or serious cardiac adverse events in healthy adults.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart RatePropranololThiazolesSphingosine 1 Phosphate Receptor ModulatorsHumansMaleFemaleAdultHealthy VolunteersYoung AdultMiddle AgedDouble-Blind MethodDrug Therapy, Combination

Stichwörter der Autor:innen

beta blockerbradycardiamultiple sclerosisponesimodpropranolol

Substanzen

PropranololponesimodThiazolesSphingosine 1 Phosphate Receptor Modulators

Autor:innen und Institutionen

  • Johnson & Johnson, Beerse, Belgium.
  • Johnson & Johnson, Leiden, the Netherlands.
  • Johnson & Johnson, Cologno Monzese, Italy.
  • Johnson & Johnson, Raritan, New Jersey, USA.
  • Johnson & Johnson, Allschwil, Switzerland.
  • Johnson & Johnson, Madrid, Spain.

ORCID-Profile: Sivi Ouwerkerk-Mahadevan, Italo Poggesi, Freya Rasschaert, Maroesja van Nimwegen-Velthuis, Juan Jose Perez-Ruixo, Tatiana Sidorenko

Zitieren

APA

Ouwerkerk-Mahadevan, S., Hosman, T., Poggesi, I., Vets, E., Rasschaert, F., Ariyawansa, J., Natarajan, J., van Nimwegen-Velthuis, M., Vaclavkova, A., Perez-Ruixo, J. J., & Sidorenko, T. (2025). A Randomized Trial on the Combined Effect of Ponesimod and Propranolol on Heart Rate, Cardiac Safety, and Pharmacokinetics in Healthy Adults. Clinical and Translational Science. https://doi.org/10.1111/cts.70341

Vancouver

Ouwerkerk-Mahadevan S, Hosman T, Poggesi I, Vets E, Rasschaert F, Ariyawansa J, et al. A Randomized Trial on the Combined Effect of Ponesimod and Propranolol on Heart Rate, Cardiac Safety, and Pharmacokinetics in Healthy Adults. Clinical and Translational Science. 2025. doi:10.1111/cts.70341

BibTeX
@article{OuwerkerkMahadevan2025,
  author = {Ouwerkerk-Mahadevan, Sivi and Hosman, Tessa and Poggesi, Italo and Vets, Eva and Rasschaert, Freya and Ariyawansa, Jay and Natarajan, Jaya and van Nimwegen-Velthuis, Maroesja and Vaclavkova, Andrea and Perez-Ruixo, Juan Jose and Sidorenko, Tatiana},
  title = {A Randomized Trial on the Combined Effect of Ponesimod and Propranolol on Heart Rate, Cardiac Safety, and Pharmacokinetics in Healthy Adults},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70341}
}
Kostenlos starten →